SCHEDULE 13G/A 0000935836-24-000779 0001440771 XXXXXXXX LIVE 1 Common Stock 03/31/2025 0001055726 Inovio Pharmaceuticals, Inc. 45773H409 660 W. Germantown Pike, Suite 110 Plymouth Meeting PA 19462 Rule 13d-1(b) Rule 13d-1(c) Stonepine Capital Management, LLC b DE 0.00 1434997.00 0.00 1434997.00 1434997.00 N 3.8 IA OO Percentage calculated based on (a) 518,331 shares of Common Stock beneficially owned by the reporting person, plus 916,666 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 36,667,221 shares of Common Stock outstanding on March 12, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024. Stonepine Capital, L.P. b DE 0.00 1434997.00 0.00 1434997.00 1434997.00 N 3.8 PN Percentage calculated based on (a) 518,331 shares of Common Stock beneficially owned by the reporting person, plus 916,666 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 36,667,221 shares of Common Stock outstanding on March 12, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024 Stonepine GP, LLC b DE 0.00 1434997.00 0.00 1434997.00 1434997.00 N 3.8 OO Percentage calculated based on (a) 518,331 shares of Common Stock beneficially owned by the reporting person, plus 916,666 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 36,667,221 shares of Common Stock outstanding on March 12, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024. Jon M. Plexico b X1 0.00 1434997.00 0.00 1434997.00 1434997.00 N 3.8 HC IN Percentage calculated based on (a) 518,331 shares of Common Stock beneficially owned by the reporting person, plus 916,666 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 36,667,221 shares of Common Stock outstanding on March 12, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024. Inovio Pharmaceuticals, Inc. 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G. 2900 NW Clearwater Drive, Suite 100-11, Bend, OR 97703 See Item 4 of the cover sheet for each reporting person. N IA HC Stonepine: 1,434,997 Partnership: 1,434,997 General Partner: 1,434,997 Jon M. Plexico: 1,434,997 Stonepine: 3.8% Partnership: 3.8% General Partner: 3.8% Jon M. Plexico: 3.8% Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 1,434,997 Partnership: 1,434,997 General Partner: 1,434,997 Jon M. Plexico: 1,434,997 Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 1,434,997 Partnership: 1,434,997 General Partner: 1,434,997 Jon M. Plexico: 1,434,997 N Y N The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G Stonepine Capital Management, LLC /s/ Jon M Plexico 05/14/2025 Stonepine Capital, L.P. /s/ Jon M. Plexico 05/14/2025 Stonepine GP, LLC /s/ Jon M. Plexico 05/14/2025 Jon M. Plexico /s/ Jon M. Plexico 05/14/2025